Literature DB >> 21140246

The next generation of gout therapeutics: ready for prime time?

Aryeh M Abeles1, Michael H Pillinger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21140246     DOI： 10.1007/s11926-010-0153-7

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


× No keyword cloud information.
  12 in total

1.  Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study.

Authors:  Alexander So; Marc De Meulemeester; Andrey Pikhlak; A Eftal Yücel; Dominik Richard; Valda Murphy; Udayasankar Arulmani; Peter Sallstig; Naomi Schlesinger
Journal:  Arthritis Rheum       Date:  2010-10

2.  Gout medication treatment patterns and adherence to standards of care from a managed care perspective.

Authors:  Chaitanya A Sarawate; Kathleen K Brewer; Wenya Yang; Pankaj A Patel; H Ralph Schumacher; Kenneth G Saag; Alan W Bakst
Journal:  Mayo Clin Proc       Date:  2006-07       Impact factor: 7.616

3.  Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

Authors:  Michael A Becker; H Ralph Schumacher; Robert L Wortmann; Patricia A MacDonald; Denise Eustace; William A Palo; Janet Streit; Nancy Joseph-Ridge
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

4.  Gout-associated uric acid crystals activate the NALP3 inflammasome.

Authors:  Fabio Martinon; Virginie Pétrilli; Annick Mayor; Aubry Tardivel; Jürg Tschopp
Journal:  Nature       Date:  2006-01-11       Impact factor: 49.962

5.  Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis.

Authors:  Gregory C Borstad; Leslie R Bryant; Michael P Abel; Daren A Scroggie; Mark D Harris; Jeff A Alloway
Journal:  J Rheumatol       Date:  2004-12       Impact factor: 4.666

6.  The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.

Authors:  Michael A Becker; H Ralph Schumacher; Luis R Espinoza; Alvin F Wells; Patricia MacDonald; Eric Lloyd; Christopher Lademacher
Journal:  Arthritis Res Ther       Date:  2010-04-06       Impact factor: 5.156

7.  Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis.

Authors:  J A Alloway; M J Moriarty; Y T Hoogland; D J Nashel
Journal:  J Rheumatol       Date:  1993-01       Impact factor: 4.666

8.  Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.

Authors:  H Ralph Schumacher; Michael A Becker; Robert L Wortmann; Patricia A Macdonald; Barbara Hunt; Janet Streit; Christopher Lademacher; Nancy Joseph-Ridge
Journal:  Arthritis Rheum       Date:  2008-11-15

9.  Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.

Authors:  John S Sundy; Michael A Becker; Herbert S B Baraf; Andre Barkhuizen; Larry W Moreland; William Huang; Royce W Waltrip; Allan N Maroli; Zeb Horowitz
Journal:  Arthritis Rheum       Date:  2008-09

10.  Molecular identification of a danger signal that alerts the immune system to dying cells.

Authors:  Yan Shi; James E Evans; Kenneth L Rock
Journal:  Nature       Date:  2003-09-07       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.